CFT8634   Click here for help

GtoPdb Ligand ID: 11965

Synonyms: CFT-8634
Compound class: Synthetic organic
Comment: CFT8634 is an orally bioavailable BRD9 degrader that was developed by C4 Therapeutics for potential to treat BRD9-dependent tumours. BRD9 degradation is predicted to offer a more effective option than BRD9 inhibition. Its chemical structure was disclosed at the AACR spring meeting in 2022.
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 7
Hydrogen bond donors 2
Rotatable bonds 9
Topological polar surface area 108.38
Molecular weight 710.34
XLogP 5.91
No. Lipinski's rules broken 1
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES COc1cc(cc(c1CN1CC[C@@H](C(C1)(F)F)N1CCN(CC1)c1ccc(cc1F)N[C@@H]1CCC(=O)NC1=O)OC)c1cn(C)c(=O)c(c1C)C
Isomeric SMILES Cc1c(c(=O)n(cc1c1cc(c(c(c1)OC)CN1CC[C@@H](C(C1)(F)F)N1CCN(CC1)c1c(cc(cc1)N[C@@H]1CCC(=O)NC1=O)F)OC)C)C
InChI InChI=1S/C37H45F3N6O5/c1-22-23(2)36(49)43(3)19-26(22)24-16-31(50-4)27(32(17-24)51-5)20-44-11-10-33(37(39,40)21-44)46-14-12-45(13-15-46)30-8-6-25(18-28(30)38)41-29-7-9-34(47)42-35(29)48/h6,8,16-19,29,33,41H,7,9-15,20-21H2,1-5H3,(H,42,47,48)/t29-,33+/m1/s1
InChI Key GNRGNRCQXHMQQV-CPBHLAHYSA-N
No information available.
Summary of Clinical Use Click here for help
In March 2022, the FDA issued Orphan Drug Designation for CFT8634 as a treatment for soft tissue sarcoma.